ZTS
$166.66
Zoetis Inc Cl A
$2.25
1.37%
ZTS
Earnings Whisper ®
N/A
4th Quarter December 2024
Consensus:  $1.38
Revenue:  $2.32 Bil
Thursday
Feb 13
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Monday, November 4, 2024

What do you expect when ZTS reports earnings?
Beat
Meet
Miss

Where is ZTS's stock price going from here?
Up
Flat
Down
Stock chart of ZTS
Analysts
Summary of analysts' recommendations for ZTS
Score
Grade
Pivots
Resistance
$172.73
$169.94
$167.17

$164.38

Support
$161.61
$158.82
$156.05
Tweet
Growth
Description
Zoetis Inc. is a leader in the animal health space with a focus on both livestock and companion animals in seven major product categories: vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. Zoetis has a diversified business, which caters to eight core species ' cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals). It directly markets its products to veterinarians and livestock producers. The outstanding growth rate in the companion animal medicines, vaccines and diagnostics sector is being driven by economic development, related increases in disposable income and a rise in pet ownership and spending on pet care.Zoetis has been working on strengthening its product portfolio through acquisitions and deals.
Peers
Vertex PharmaceuticalsBioMarin PharmaceuticalARRAY TechnologiesRegeneron PharmaceuticalsMerck & Co.Bristol Myers SquibbEli LillyPfizerJohnson & JohnsonUltragenyx Pharmaceutical